Aptevo Therapeutics (APVO) Tax Provisions (2015 - 2019)

Aptevo Therapeutics (APVO) posted Tax Provisions of -$999000.0 for Q3 2019, down 135.38% sequentially from $2.8 million in Q4 2017.

Aptevo Therapeutics (APVO) Tax Provisions (2015 - 2019) Analysis & Trends

Aptevo Therapeutics has reported Tax Provisions for 4 years, with the latest figure at -$999000.0 in Q3 2019.

Quarterly Tax Provisions changed N/A year-over-year to -$999000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was -$12.9 million (changed N/A YoY) and the FY2017 annual result came in at -$12.8 million, up 35.19% from the prior year.
Tax Provisions retreated to -$999000.0 in Q3 2019 per APVO's latest filing, from $2.8 million in the prior quarter.
Over five years, Tax Provisions peaked at $2.8 million in Q4 2017 and troughed at -$17.6 million in Q3 2016.
A 4-year average of -$2.8 million and a median of -$717500.0 in 2015 frame the typical range for Tax Provisions.
The widest YoY moves for Tax Provisions: up 356.26% in 2017, down 8954.55% in 2017.
Over 4 years, Tax Provisions stood at -$610000.0 in 2015, then plunged by 80.66% to -$1.1 million in 2016, then soared by 356.26% to $2.8 million in 2017, then slumped by 135.38% to -$999000.0 in 2019.
According to Business Quant data, Tax Provisions over the past three periods registered -$999000.0, $2.8 million, and -$13.8 million for Q3 2019, Q4 2017, and Q3 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	59.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Aptevo Therapeutics	3.18 Mn	-6.61 Mn	-	-

Download Data